Podimo is an audio entertainment subscription company that focuses on creating an ecosystem for podcasters by compensating creators for their work. The platform offers a diverse range of podcasts, including popular shows and exclusive content from both established and emerging hosts. This variety allows users to access a wide selection of podcasts at their convenience, enhancing the listening experience. By prioritizing the needs of podcasters and fostering a supportive environment for content creation, Podimo aims to change the landscape of audio entertainment.
Trusted by leading healthcare providers to enhance millions of patient interactions, with seamless integration into your workflow.
Kobaj provides co-buying, community, e-commerce, winemakers, wine, platform, and marketplace services. They also provide beverage manufacturing, payment, fees, insurance, and transport of the goods.
No one reads the product manual. Enhance your product experience and serve your customers with a smart product Assistant Interactive and effective product onboarding. Re-focus from product instructions to interactive customer experiences.
The Forecast AI-native platform represents the most advanced technology ever applied to managing projects, resources and finances. Our platform automates busywork, surfaces best practices, predicts outcomes, guides projects to success, and most importantly empowers every team member to do their best work. Forecast is the ultimate upgrade for project teams and professional services organizations. Technology doing what it does best, so humans can do what they do best.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
No one reads the product manual. Enhance your product experience and serve your customers with a smart product Assistant Interactive and effective product onboarding. Re-focus from product instructions to interactive customer experiences.
SoundBoks is a hardware start-up founded in January 2015, with headquarters in Mountain View, California, and an additional office in San Francisco. The company specializes in designing and manufacturing battery-powered outdoor speakers, which are particularly suited for outdoor gatherings, sports events, and festivals. Known for their shock and weatherproof construction, SoundBoks speakers are portable and durable, offering up to 60 hours of battery life at high volumes. The speakers feature high sound pressure level (SPL) units paired with a powerful amplifier, capable of reaching sound outputs of up to 119 decibels. SoundBoks aims to enhance outdoor music experiences, allowing users to take their sound systems anywhere.
Finematter is an online store that offers a curated selection of independent designer jewelry with free shipping and a one-year warranty. Finematter assists independent creatives and entrepreneurs in expanding their businesses beyond a single store without sacrificing their creative integrity. Finematter sources from independent jewelry artists, displaying a selection of design-leading pieces, allowing customers to browse and buy high-end jewelry while knowing that Finematter's experts will guide them on design, materials, and provenance.
Podimo is an audio entertainment subscription company that focuses on creating an ecosystem for podcasters by compensating creators for their work. The platform offers a diverse range of podcasts, including popular shows and exclusive content from both established and emerging hosts. This variety allows users to access a wide selection of podcasts at their convenience, enhancing the listening experience. By prioritizing the needs of podcasters and fostering a supportive environment for content creation, Podimo aims to change the landscape of audio entertainment.
BLAST Premier is an esports entertainment company that specializes in broadcast studio shows, arena events, and online content.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
The Forecast AI-native platform represents the most advanced technology ever applied to managing projects, resources and finances. Our platform automates busywork, surfaces best practices, predicts outcomes, guides projects to success, and most importantly empowers every team member to do their best work. Forecast is the ultimate upgrade for project teams and professional services organizations. Technology doing what it does best, so humans can do what they do best.
Astralis is a professional e-sports organization which represents one of the best Counter-Strike teams in the world. Astralis is an eSport franchise founded by Frederik Byskov and Jacob Lund Kristensen along with the five founding players Andreas “Xyp9x” Højsleth, René “cajunb” Borg, Nicolai “dev1ce” Reedtz, Finn “karrigan” Andersen and Peter “dupreeh” Rasmussen of the CounterStrike team. The team is consistently ranking among the top three CounterStrike teams globally. In January 2016, Sunstone led the Seed round into the company with participation of former Podio CEO and angel investor Tommy Ahlers.
Podimo is an audio entertainment subscription company that focuses on creating an ecosystem for podcasters by compensating creators for their work. The platform offers a diverse range of podcasts, including popular shows and exclusive content from both established and emerging hosts. This variety allows users to access a wide selection of podcasts at their convenience, enhancing the listening experience. By prioritizing the needs of podcasters and fostering a supportive environment for content creation, Podimo aims to change the landscape of audio entertainment.
Peakon automatically collects employee feedback, analyses it, and then delivers the insights needed to improve businesses - in real-time. Peakon is able to provide insights and suggested actions that are proven to work — based on the success of some of the world’s leading organizations. The Peakon platform works everywhere, for everyone. Peakon is translated into 50+ languages, can deal with complex organizational structures, and is able to handle tens of thousands of employees. Employees submit feedback via the web, mobile browser, SMS, kiosk, or native app.
Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.
RFRSH Entertainment is an esports marketing and media rights company working with a growing number of the best esports teams - established organisations as well as a new crop of player-owned teams. We are the professional force behind the teams that builds their brand and enhances sports performance to accel teams into top placements. They represent the team’s commercial and media rights, connecting them with the top brands in the world for sponsorships and marketing agreements.
Templafy’s next gen document generation platform automates all business document creation across organizations to activate and protect brands, drive governance and enable better document creation at any complexity and scale. We uniquely leverage content enablement technology that intelligently connects content to users where they already work, when it matters most. From immediate access to on-brand company templates directly within Microsoft Office to fully automated compilation of a sales proposal within Salesforce and every content workflow between and beyond, our platform enables employees to create compliant, on-brand, high-performing business documents faster. Founded in Denmark in 2014, Templafy is an international organization that supports millions of users across more than 800 enterprise customers globally – including KPMG, IKEA, BDO, and more. With $200 million in funding raised, Templafy is backed by industry-leading investors such as Insight Partners, Seed Capital, Dawn Capital, Damgaard Company and Golub Capital.
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
We want to create new standards for the workplace pension industry that has not renewed itself for years by making a digital self service pension solution. We offer digital onboarding and advisory service at a low cost, our customers receive support within minutes and our goal is to constantly innovate our product to fulfill our consumers' ever changing needs. Grandhood is the next generation workplace pension solution for all companies embracing the digital age.
Private Equity Round in 2018
Blackwood Seven is a media analytics platform which strives to increase the effect of company’s media spend using our predictive analytics framework built on machine learning and artificial intelligence. Using real-time modelling and advanced KPI prediction we are able to increase a company’s media ROI by up to 15-25%.
The Forecast AI-native platform represents the most advanced technology ever applied to managing projects, resources and finances. Our platform automates busywork, surfaces best practices, predicts outcomes, guides projects to success, and most importantly empowers every team member to do their best work. Forecast is the ultimate upgrade for project teams and professional services organizations. Technology doing what it does best, so humans can do what they do best.
Trusted by leading healthcare providers to enhance millions of patient interactions, with seamless integration into your workflow.
Peakon automatically collects employee feedback, analyses it, and then delivers the insights needed to improve businesses - in real-time. Peakon is able to provide insights and suggested actions that are proven to work — based on the success of some of the world’s leading organizations. The Peakon platform works everywhere, for everyone. Peakon is translated into 50+ languages, can deal with complex organizational structures, and is able to handle tens of thousands of employees. Employees submit feedback via the web, mobile browser, SMS, kiosk, or native app.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
RFRSH Entertainment is an esports marketing and media rights company working with a growing number of the best esports teams - established organisations as well as a new crop of player-owned teams. We are the professional force behind the teams that builds their brand and enhances sports performance to accel teams into top placements. They represent the team’s commercial and media rights, connecting them with the top brands in the world for sponsorships and marketing agreements.
Peakon automatically collects employee feedback, analyses it, and then delivers the insights needed to improve businesses - in real-time. Peakon is able to provide insights and suggested actions that are proven to work — based on the success of some of the world’s leading organizations. The Peakon platform works everywhere, for everyone. Peakon is translated into 50+ languages, can deal with complex organizational structures, and is able to handle tens of thousands of employees. Employees submit feedback via the web, mobile browser, SMS, kiosk, or native app.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Kaisa is Customer Engagement Platform that helps global brands design connected journeys that are personalized at every step. The platform brings together all the tools companies and their sellers need to design & automate personalized CX, at scale.
Blackwood Seven is a media analytics platform which strives to increase the effect of company’s media spend using our predictive analytics framework built on machine learning and artificial intelligence. Using real-time modelling and advanced KPI prediction we are able to increase a company’s media ROI by up to 15-25%.
Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.
Trusted by leading healthcare providers to enhance millions of patient interactions, with seamless integration into your workflow.
Peakon automatically collects employee feedback, analyses it, and then delivers the insights needed to improve businesses - in real-time. Peakon is able to provide insights and suggested actions that are proven to work — based on the success of some of the world’s leading organizations. The Peakon platform works everywhere, for everyone. Peakon is translated into 50+ languages, can deal with complex organizational structures, and is able to handle tens of thousands of employees. Employees submit feedback via the web, mobile browser, SMS, kiosk, or native app.
Astralis is a professional e-sports organization which represents one of the best Counter-Strike teams in the world. Astralis is an eSport franchise founded by Frederik Byskov and Jacob Lund Kristensen along with the five founding players Andreas “Xyp9x” Højsleth, René “cajunb” Borg, Nicolai “dev1ce” Reedtz, Finn “karrigan” Andersen and Peter “dupreeh” Rasmussen of the CounterStrike team. The team is consistently ranking among the top three CounterStrike teams globally. In January 2016, Sunstone led the Seed round into the company with participation of former Podio CEO and angel investor Tommy Ahlers.
Templafy’s next gen document generation platform automates all business document creation across organizations to activate and protect brands, drive governance and enable better document creation at any complexity and scale. We uniquely leverage content enablement technology that intelligently connects content to users where they already work, when it matters most. From immediate access to on-brand company templates directly within Microsoft Office to fully automated compilation of a sales proposal within Salesforce and every content workflow between and beyond, our platform enables employees to create compliant, on-brand, high-performing business documents faster. Founded in Denmark in 2014, Templafy is an international organization that supports millions of users across more than 800 enterprise customers globally – including KPMG, IKEA, BDO, and more. With $200 million in funding raised, Templafy is backed by industry-leading investors such as Insight Partners, Seed Capital, Dawn Capital, Damgaard Company and Golub Capital.
Blackwood Seven is a media analytics platform which strives to increase the effect of company’s media spend using our predictive analytics framework built on machine learning and artificial intelligence. Using real-time modelling and advanced KPI prediction we are able to increase a company’s media ROI by up to 15-25%.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Issuu is digital publishing and discovery platform that connects people to content for which they have great passion, created by publishers large and small, that share that passion. A digital publishing service that reimagines the print experience, Issuu hosts over 17 million publications and serves over 5.5 billion page-views to over 80 million active readers each month. The site features leading and emerging titles in fashion, culture, arts, hobbies, catalogs and hyperlocal content, all of which are accessible on any device. Issuu was founded in Copenhagen, Denmark in 2006 by Michael Hansen, Ruben Bjerg Hansen, Mikkel Jensen, and Martin Ferro-Thomsen, a self-avowed group of “mad geeks with a love of the publishing industry.” Originally focused on democratizing print media, the company has succeeded in giving aspiring and established publishers the chance to create their own digital magazines without sacrificing the aesthetic and tactile experience of print. With that goal firmly in mind, Issuu launched in December 2007. In 2008, the site was a SXSW finalist. In 2009, TIME named Issuu one of the 50 Best Websites, and the company was also listed as a Webby Awards honoree. In early 2013, the now transatlantic company opened an office in Palo Alto, California and appointed a new CEO, Joe Hyrkin, formerly of Reverb, Trinity Ventures, and Yahoo, to lead the company globally.
Templafy’s next gen document generation platform automates all business document creation across organizations to activate and protect brands, drive governance and enable better document creation at any complexity and scale. We uniquely leverage content enablement technology that intelligently connects content to users where they already work, when it matters most. From immediate access to on-brand company templates directly within Microsoft Office to fully automated compilation of a sales proposal within Salesforce and every content workflow between and beyond, our platform enables employees to create compliant, on-brand, high-performing business documents faster. Founded in Denmark in 2014, Templafy is an international organization that supports millions of users across more than 800 enterprise customers globally – including KPMG, IKEA, BDO, and more. With $200 million in funding raised, Templafy is backed by industry-leading investors such as Insight Partners, Seed Capital, Dawn Capital, Damgaard Company and Golub Capital.
FBC Device ApS, founded in 2005 and based in Risskov, Denmark, specializes in the manufacture and marketing of spinal fusion implants. The company achieved its first significant milestone in 2013 when its Statur product line received the CE mark, allowing it to enter the European and Canadian markets. FBC Device has also obtained ISO 13485 certification, reflecting its commitment to high-quality standards. Its innovative two-piece anterior interbody fusion implant incorporates tantalum spheres as radiologic markers, enabling surgeons to adjust lordosis during procedures. This technology aims to improve patient outcomes by offering a self-adapting ALIF cage that positively influences sagittal balance. The company holds patents in Europe and the United States, further solidifying its position in the spinal implant industry.
Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.
addwish is a provider of wish list services for both consumers and online shops. Consumers can easily create wishlists to share with their family and friends. The highly intuitive interface on both addwish.com and on its iOS and Android mobile apps makes gift giving easier than ever before. For online retailers, addwish supplies a webshop plugin that enables the addwish functionality directly on their websites. As added benefit for the merchants, addwish promotes and suggests the products from their webshops to its users, resulting in traffic and lead generation.
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Blackwood Seven is a media analytics platform which strives to increase the effect of company’s media spend using our predictive analytics framework built on machine learning and artificial intelligence. Using real-time modelling and advanced KPI prediction we are able to increase a company’s media ROI by up to 15-25%.
Mofibo started in Copenhagen (2013) as one of the world’s first book subscription services. We are currently in three countries and will be expanding into more countries within the next 12 months. Our overall goal is to transform the way millions of people interact with books, through using a data-driven and customer centric approach to fundamentally change the reading experience crosses multiple countries.
Kaisa is Customer Engagement Platform that helps global brands design connected journeys that are personalized at every step. The platform brings together all the tools companies and their sellers need to design & automate personalized CX, at scale.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies. Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreements with Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $ 4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, Sunstone Capital, SLS Invest and Novo A/S.
Adenium Biotech is a Danish biopharmaceutical company spun out from Novozymes A/S in 2011. Adenium focuses on the development and commercialization of novel antibiotics for the treatment of multi drug resistant bacterial infections. Our focus is treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. Complicated urinary tract infections are caused by predominantly Gram-negative bacteria and in particular Escherichia coli. E. coli is also a frequent cause of many other common bacterial infections such as cholecystitis, bacteremia, cholangitis and traveler’s diarrhea, as well as other clinical infections such as neonatal meningitis and pneumonia. Most Infections caused by Escherichia coli are relative easy to cure, however, hospital adapted strains of Escherichia coli are often multi-resistant and are able to cause life threatening infections. Hospital acquired pneumonia (HAP) or ventilator acquired pnemonia (VAP) are also indications dominated by Gram-negative bacteria and in particular Pseudomonas aeruginosa and Klebsiella pneumoniae. P. aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It is the most common pathogen isolated from patients who have been hospitalized longer than 1 week and it is a frequent cause of nosocomial infections such as pneumonia, UTIs, and bacteremia. Infections caused by Klebsiella and Pseudomonas are complicated since many Pseudomonas aeruginosa and Klebsiella pneumoniae strains are multi drug resistant. Infections caused by Acinetobacter are rare and most strains found outside hospitals are sensitive to antibiotics. While Acinetobacter poses few risks to healthy individuals, a few species, particularly Acinetobacter baumannii, can cause serious infections – mainly in very ill trauma and hospitalized patients increasing the post trauma mortality as seen in wounded soldiers in the wars in Afghanistan and Iraq. The most common Acinetobacter infections include pneumonia, bacteraemia, wound infections, and urinary tract infections. ‘Hospital-adapted’ strains of Acinetobacter are often resistant to antibiotics and are increasingly difficult to treat. Adenium Biotech strives to find a novel treatment for multi-resistant Acinetobacter. Arenicin is a non haemolytic and non cytotoxic 21 amino acids antimicrobial peptide isolated from the lugworm. Arenicin has a strong and selective efficacy against Gram negative bacteria as well as a broad therapeutic window. Ten Arenicin variants were selected and subjected to a ranking program consisting of toxicology as well as in vitro and in vivo efficacy profiling. The three highest ranking Arenicin variants were selected in December 2013 for final lead optimization and selection of an Arenicin lead product candidate early in the fourth quarter 2013. Adenium Biotech is a semi-virtual biotech company with a small group of experts that supported by an international scientific advisory board focus on bringing the Arenicin program through clinical development to NDA filing.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Podio, now part of Citrix, is a collaborative work platform with a new take on how everyday-work gets done. Podio gives people more power than they've ever had before to manage their work better, smarter and in their own way. Combining hundreds of specialized and flexible work apps with messaging, tasks, reporting, workflow and contact management, Podio lets you build and shape the online workplace most fitting to your role. It eliminates scattered, unorganized work routines, and replaces multiple products from different companies with a single environment and a single login. Podio is already trusted by thousands of teams, companies and organizations worldwide who use it to facilitate a particular work process or to connect all their work activity. Currently based in Copenhagen, Podio is building a multinational team of German, French, British, and Danish employees. Thomas Madsen-Mygdal is chair of the board of directors. Tommy Ahlers, formerly of Zyb, is CEO and investor.
Acarix A/S is based on pioneering research performed at the Aalborg University, Denmark, initiated in 2004. The research group received the award, ‘MedicoPrisen’, from Medicoindustrien (Danish Medtech trade association) in 2007. A research and development collaboration was established in 2007 between Aalborg University and Coloplast A/S, receiving public support from the Danish National Advanced Technology Foundation in 2008. Acarix A/S was established in 2009 as a spin-out company from Coloplast A/S with Coloplast A/S and Aalborg University as the major shareholders. In 2010 Acarix A/S succeeded attracting venture capital from Seed Capital (DK), Sunstone Capital (DK) and Seventure Partners (F). In 2011 Acarix A/S and collaborators furthermore achieved funding of 5.3 million DKK from the Danish Business Innovation Fund.
Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modified ÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
Biomonitor was founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen and has since its inception grown rapidly. The foundation of the company is based on Professor Klaus Bendtzen’s many years of experience from his research work at the Copenhagen University Hospital on inflammation and immunology. Prof. Klaus Bendtzen discovered through his work how some patients form antibodies against those proteins and peptides that are used in biopharmaceutical products for the treatment of a range of chronic diseases. Antibodies can neutralize the biopharmaceuticals that patients receive and patients with antibodies thereby do not or only marginally benefit from such treatments so it became crucial to develop methods to monitor biopharmaceuticals.
Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modified ÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.
**World's largest library of user generated, shareable analytics apps** youcalc let's business people create and share custom reports and analytics on data from SaaS systems — zero coding required! A user driven library of now more than 130 analytics apps for CRM, sales, marketing, service/support and project management, and live data connection to a growing number of SaaS systems (Salesforce.com, Basecamp, AdWords, Google Analytics, Highrise CRM, MailChimp, etc.) **User driven innovation and collaboration** The reporting needs of e.g. sales people are different, but a sales guy in New York may share "custom needs" with a sales guy in another company in Rome. youcalc's mission is to create the world's largest library of analytics apps by allowing business users to create and share analytics apps. All apps built on youcalc become public from the app library, for anyone to use as is or customize to individual needs. All customized apps go back into the app library for the benefit of other users. youcalc let's business users across the world search and use a vast library of analytics apps built by other users with similar needs. **Run anywhere - in iGoogle, inside e.g. Salesforce.com, on intranets, on iPhones, etc.** youcalc apps are easy-to-use, interactive, Flash charts that run anywhere - built for business users, not for expert analysts! Stop spending hours clicking through expert analytics interfaces. Business users get the exact analysis they need, with one click, anywhere they want. Add several apps to iGoogle and you have a personal portal for reporting across all your SaaS systems.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
Issuu is digital publishing and discovery platform that connects people to content for which they have great passion, created by publishers large and small, that share that passion. A digital publishing service that reimagines the print experience, Issuu hosts over 17 million publications and serves over 5.5 billion page-views to over 80 million active readers each month. The site features leading and emerging titles in fashion, culture, arts, hobbies, catalogs and hyperlocal content, all of which are accessible on any device. Issuu was founded in Copenhagen, Denmark in 2006 by Michael Hansen, Ruben Bjerg Hansen, Mikkel Jensen, and Martin Ferro-Thomsen, a self-avowed group of “mad geeks with a love of the publishing industry.” Originally focused on democratizing print media, the company has succeeded in giving aspiring and established publishers the chance to create their own digital magazines without sacrificing the aesthetic and tactile experience of print. With that goal firmly in mind, Issuu launched in December 2007. In 2008, the site was a SXSW finalist. In 2009, TIME named Issuu one of the 50 Best Websites, and the company was also listed as a Webby Awards honoree. In early 2013, the now transatlantic company opened an office in Palo Alto, California and appointed a new CEO, Joe Hyrkin, formerly of Reverb, Trinity Ventures, and Yahoo, to lead the company globally.
**World's largest library of user generated, shareable analytics apps** youcalc let's business people create and share custom reports and analytics on data from SaaS systems — zero coding required! A user driven library of now more than 130 analytics apps for CRM, sales, marketing, service/support and project management, and live data connection to a growing number of SaaS systems (Salesforce.com, Basecamp, AdWords, Google Analytics, Highrise CRM, MailChimp, etc.) **User driven innovation and collaboration** The reporting needs of e.g. sales people are different, but a sales guy in New York may share "custom needs" with a sales guy in another company in Rome. youcalc's mission is to create the world's largest library of analytics apps by allowing business users to create and share analytics apps. All apps built on youcalc become public from the app library, for anyone to use as is or customize to individual needs. All customized apps go back into the app library for the benefit of other users. youcalc let's business users across the world search and use a vast library of analytics apps built by other users with similar needs. **Run anywhere - in iGoogle, inside e.g. Salesforce.com, on intranets, on iPhones, etc.** youcalc apps are easy-to-use, interactive, Flash charts that run anywhere - built for business users, not for expert analysts! Stop spending hours clicking through expert analytics interfaces. Business users get the exact analysis they need, with one click, anywhere they want. Add several apps to iGoogle and you have a personal portal for reporting across all your SaaS systems.